Integrated BioPharma, Inc. (INBP) has released its financial results for the fiscal year ended June 30, 2026, and the three months ended on that date. The company reported total revenue of $43.9 million for the fiscal year, a decrease of $10.5 million or 19.3% compared to the prior fiscal year. For the quarter ended June 30, 2026, revenue was $9.8 million, down 31.0% from the $14.2 million reported in the same period the previous year.
The company recorded an operating loss of approximately $2.7 million for fiscal year 2026, compared to operating income of $2.0 million in fiscal year 2025. In the most recent quarter, Integrated BioPharma reported an operating loss of $0.9 million, whereas it recorded operating income of approximately $0.6 million in the prior year's quarter.
Net results for the fiscal year ended June 30, 2026, showed a net loss of approximately $2.8 million, or $0.09 per share. This compares to net income of approximately $0.8 million, or $0.03 per share, for the fiscal year ended June 30, 2025. For the quarter ended June 30, 2026, the company reported a net loss of approximately $1.4 million, or $0.04 per share.
Integrated BioPharma operates primarily in the manufacturing, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products. The company’s two largest customers in its Contract Manufacturing Segment represented approximately 90% of total revenue in fiscal year 2026 and 84% in fiscal year 2025.
